Literature DB >> 26055236

Further analysis of the emotional consequences of head and neck cancer as reflected by the Patients' Concerns Inventory.

A Kanatas1, G Humphris2, D Lowe3, S N Rogers4.   

Abstract

Patients with cancer of the head and neck can experience high levels of distress. The emotional burden of the disease must be recognised and important negative emotions assessed so that appropriate interventions can be provided. We obtained data from 1482 head and neck cancer Patients' Concerns Inventories (HNC-PCI) completed by 813 patients between 1 August 2007 and 9 January 2013, and particularly concentrated on the psychological, emotional, and spiritual well-being domain, which comprises 14 items. We also assessed health-related quality of life (HRQoL) using the University of Washington quality of life questionnaire version 4 (UWQoL). A total of 538 patients were male and the mean age of all patients on first completing the PCI was 64 years (range 20-94). Primary tumours were oral (n=392, 48%), oropharyngeal (n=196, 24%), laryngeal (n=142, 17%), other (n=74, 9%), or unknown (n=9, 1%). Fifty-one percent of patients (n=753) chose no items in the emotions category, 16% (n=236) identified fear of recurrence only, 16% (n=236) selected items other than fear of recurrence, and 17% (n=257) selected fear of recurrence and others. Patients who identified fear of recurrence with other issues had significantly worse scores for anxiety, mood, and overall quality of life (QoL). Fear of recurrence is common but patients with multiple emotional concerns need additional support, and further research is required to specify the practical details of the interventions needed at various points during and after treatment.
Copyright © 2015 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Fear of recurrence; Head and Neck Cancer; Patient Concerns Inventory

Mesh:

Year:  2015        PMID: 26055236     DOI: 10.1016/j.bjoms.2015.02.026

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN: 0266-4356            Impact factor:   1.651


  6 in total

Review 1.  Assessment of patient concerns: a review.

Authors:  Jemima Nilan; Deepak Doltani; Dominic Harmon
Journal:  Ir J Med Sci       Date:  2018-01-24       Impact factor: 1.568

2.  Priorities of human papillomavirus-associated oropharyngeal cancer patients at diagnosis and after treatment.

Authors:  Melina J Windon; Carole Fakhry; Farhoud Faraji; Tanya Troy; Christine G Gourin; Ana P Kiess; Wayne Koch; David W Eisele; Gypsyamber D'Souza
Journal:  Oral Oncol       Date:  2019-06-04       Impact factor: 5.337

3.  Improving quality of life through the routine use of the patient concerns inventory for head and neck cancer patients: a cluster preference randomized controlled trial.

Authors:  Simon N Rogers; Derek Lowe; Cher Lowies; Seow Tien Yeo; Christine Allmark; Dominic Mcavery; Gerald M Humphris; Robert Flavel; Cherith Semple; Steven J Thomas; Anastasios Kanatas
Journal:  BMC Cancer       Date:  2018-04-18       Impact factor: 4.430

4.  An Economic Evaluation Supported by Qualitative Data About the Patient Concerns Inventory (PCI) versus Standard Treatment Pathway in the Management of Patients with Head and Neck Cancer.

Authors:  Victory 'Segun Ezeofor; Llinos Haf Spencer; Simon N Rogers; Anastasios Kanatas; Derek Lowe; Cherith J Semple; Jeffrey R Hanna; Seow Tien Yeo; Rhiannon Tudor Edwards
Journal:  Pharmacoecon Open       Date:  2022-01-31

Review 5.  Health-Related Quality of Life, Psychosocial Distress and Unmet Needs in Older Patients With Head and Neck Cancer.

Authors:  Lachlan McDowell; Danny Rischin; Karla Gough; Christina Henson
Journal:  Front Oncol       Date:  2022-02-15       Impact factor: 6.244

Review 6.  The Patient Concerns Inventory in head and neck oncology: a structured review of its development, validation and clinical implications.

Authors:  Anastasios Kanatas; Derek Lowe; Simon N Rogers
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-07-17       Impact factor: 3.236

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.